Sofosbuvir Form-M3 Crystalline Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing sofosbuvir lack a stable crystalline form that ensures long-term physical and chemical stability, which is crucial for its effectiveness as an HCV inhibitor.
Innovation Solution
A novel crystalline form of sofosbuvir, designated as form-M3, is developed, characterized by specific PXRD patterns and prepared through a process involving dissolution in a water-miscible solvent, addition of an anti-solvent, and seeding, followed by isolation, which enhances its stability and pharmaceutical characteristics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for preparing sofosbuvir are used, then the compound can be synthesized, but it lacks long-term physical and chemical stability
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing multiple crystalline forms (polymorphs) of sofosbuvir with different physical properties. Specifically, the invention identifies crystalline forms with distinct PXRD patterns, melting points, and stability characteristics. By changing the crystalline structure parameters through controlled crystallization processes using different solvents and anti-solvents, the patent achieves a stable form (Form M3) that maintains purity and stability for up to six months under various storage conditions.
2Reliability
If a stable crystalline form is developed, then long-term stability is achieved, but the preparation process becomes more complex
Solution Approach 1:
The patent applies preliminary action by performing thorough characterization of each crystalline form before selecting the optimal one for pharmaceutical use. The invention systematically investigates PXRD patterns, DSC thermograms, and storage stability of multiple polymorphs beforehand. This preliminary characterization work identifies Form M3 as the most stable crystalline form, allowing the development of a standardized preparation process that avoids later stability issues without requiring complex modifications to the synthesis route.
3Reliability
If multiple crystalline forms are characterized, then the most stable form can be identified, but the investigation time and resources increase
Solution Approach 1:
The patent applies phase transitions by systematically inducing and characterizing different crystalline phases of sofosbuvir through controlled crystallization from various solvents and anti-solvent systems. The invention uses differential scanning calorimetry (DSC) to detect phase transitions and melting points, and X-ray powder diffraction (PXRD) to characterize the crystal structures. This approach efficiently identifies stable polymorphs like Form M3 by exploiting the relationship between crystalline phase stability and physical properties, reducing the time needed to screen multiple forms compared to trial-and-error methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline sofosbuvir form-M3 exhibits long-term physical and chemical stability, maintaining its purity and moisture content for up to six months under various storage conditions, making it suitable for pharmaceutical formulations such as tablets or capsules for treating hepatitis C.
Implementation Method 1
dissolving sofosbuvir in a solvent to form a solution
Implementation Method 2
adding an anti-solvent to the solution; and isolating crystalline sofosbuvir form-M3
Implementation Method 3
isolating crystalline sofosbuvir form-M3
Data Source
AI summary
The present disclosure provides novel crystalline sofosbuvir form-M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage forms.